Company Filing History:
Years Active: 2014-2016
Title: Fei Su: Innovator in Combination Therapy for Proliferative Disorders
Introduction
Fei Su is a notable inventor based in Paramus, NJ (US), recognized for his contributions to the field of medicine, particularly in the development of combination therapies for proliferative disorders. He holds a total of 4 patents, showcasing his innovative approach to treating complex medical conditions.
Latest Patents
Among his latest patents, Fei Su has developed a combination therapy for proliferative diseases that utilizes a b-Raf inhibitor and an MDM2 inhibitor. This groundbreaking treatment aims to address various proliferative disorders effectively. Another significant patent involves a combination therapy that includes propane-1-sulfonic acid and an interferon, specifically targeting patients suffering from solid tumors such as colorectal cancer, melanoma, and thyroid cancer. Notably, this therapy is designed for cases where the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
Career Highlights
Fei Su has had a distinguished career, working with prominent companies in the pharmaceutical industry. He has been associated with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG, where he has contributed to significant advancements in medical treatments.
Collaborations
Throughout his career, Fei Su has collaborated with esteemed colleagues, including Brian Higgins and Kenneth Kolinsky, further enhancing the impact of his work in the field of medicine.
Conclusion
Fei Su's innovative contributions to combination therapies for proliferative disorders highlight his commitment to advancing medical science. His work continues to pave the way for new treatment options that can significantly improve patient outcomes.